Celcuity (NASDAQ:CELC) Raised to “Hold” at Wall Street Zen

Celcuity (NASDAQ:CELC) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other equities research analysts have also recently issued reports on CELC. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, October 8th. Leerink Partners increased their target price on Celcuity from $28.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday, July 28th. HC Wainwright raised their price target on Celcuity from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Monday, August 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $70.00 price objective on shares of Celcuity in a research note on Friday, October 3rd. Finally, Guggenheim assumed coverage on shares of Celcuity in a report on Monday, September 22nd. They set a “buy” rating on the stock. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Celcuity currently has a consensus rating of “Moderate Buy” and an average price target of $56.50.

Celcuity Stock Performance

NASDAQ:CELC opened at $51.96 on Friday. The firm has a 50 day simple moving average of $51.77 and a 200-day simple moving average of $27.69. The company has a debt-to-equity ratio of 2.24, a current ratio of 4.58 and a quick ratio of 4.58. The firm has a market cap of $2.20 billion, a PE ratio of -15.06 and a beta of 0.70. Celcuity has a 1-year low of $7.57 and a 1-year high of $63.06.

Celcuity (NASDAQ:CELC) last announced its earnings results on Thursday, August 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.14). On average, equities analysts expect that Celcuity will post -2.62 EPS for the current year.

Insider Buying and Selling

In other Celcuity news, Director David Dalvey sold 100,000 shares of the company’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $43.98, for a total transaction of $4,398,000.00. Following the completion of the sale, the director directly owned 125,000 shares in the company, valued at $5,497,500. This represents a 44.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 15.78% of the stock is owned by corporate insiders.

Institutional Trading of Celcuity

Institutional investors have recently modified their holdings of the company. Avanza Fonder AB acquired a new stake in Celcuity during the 3rd quarter worth approximately $79,000. Harbor Capital Advisors Inc. purchased a new stake in Celcuity during the third quarter worth approximately $399,000. Red Door Wealth Management LLC acquired a new stake in shares of Celcuity in the third quarter worth $389,000. Tower Research Capital LLC TRC lifted its holdings in shares of Celcuity by 211.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after acquiring an additional 3,766 shares in the last quarter. Finally, Captrust Financial Advisors boosted its position in Celcuity by 2.3% during the 2nd quarter. Captrust Financial Advisors now owns 570,441 shares of the company’s stock worth $7,615,000 after purchasing an additional 12,838 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.